Description: BiomX Inc., a clinical-stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from dysbiosis of the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases, primary sclerosing cholangitis, and cancer. The company is based in Ness Ziona, Israel.
Home Page: www.biomx.com
PHGE Technical Analysis
22 Einstein Street
Ness Ziona,
7414003
Israel
Phone:
972 7 2394 2377
Officers
| Name | Title |
|---|---|
| Mr. Jonathan Eitan Solomon MBA | CEO & Director |
| Mr. Assaf Oron | Chief Bus. Officer |
| Dr. Merav Bassan Ph.D. | Chief Devel. Officer |
| Prof. Rotem Sorek Ph.D. | Scientific Founder |
| Dr. Eran Elinav M.D., Ph.D. | Scientific Founder |
| Dr. Timothy K. Lu M.D., Ph.D. | Scientific Founder |
| Ms. Marina Wolfson CPA | CFO & Sec. |
| Ms. Inbal Benjamini-Elran | C.H.R.O |
| Dr. Inbar Gahali-Sass | VP of Platform R&D |
| Dr. Regis A. Vilchez M.D., Ph.D. | Sr. VP & Head of Clinical Devel. |
Exchange: NYSE MKT
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1796 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-03-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 103 |